Quality of Botulinum Toxin for Human Treatment
The crystallized botulinum toxin type A now used in treatment, Batch 79-11 prepared in November 1979 and licensed as an Orphan drug by the FDA in December 1989, has served well for treatment of many human dystonias and other involuntary muscle movement disorders. The continued production of high quality botulinum toxin presents some important problems that must be investigated. In this presentation we wish to make some proposals that should improve the quality of the toxin as a pharmaceutical.
KeywordsBotulinum Toxin Orphan Drug Botulinum Toxin Type Clostridium Botulinum Spasmodic Torticollis
Unable to display preview. Download preview PDF.
- 2.Patterson-Curtis S, Johnson EA. Regulation of neurotoxin and protease formation in Clostridium botulinum Okra B and Hall A by arginine. Appl Environ Microbiol 1989; 55: 1544–1548.Google Scholar
- 3.Schantz EJ, Kautter DA. Standardized assay for Clostridium botulinum toxins. J Assoc Off Anal 1978; 61: 96–99.Google Scholar